Nipocalimab

ATC Code L04AL03

Nipocalimab

Definition

A fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn), with potential immunomodulating activity. Upon administration, nipocalimab targets and binds to FcRn at the immunoglobulin G (IgG) binding site, thereby preventing the interaction between FcRn and the serum protein IgG. By preventing FcRn/IgG binding, nipocalimab blocks the FcRn-mediated rescue of IgG, enables IgG degradation and prevents IgG-mediated inflammation. IgG plays a key role in many autoimmune diseases and is an important factor in inflammatory processes.

Also known as M 281, M-281, M281, NIPOCALIMAB — per NCIT

Also identified as

Indications

Disease Relation Source
Myasthenia gravis may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Musculature may treat a disease of this organ DERIVED · CC BY 4.0
Musculoskeletal system may treat a disease of this organ DERIVED · CC BY 4.0
Nervous system may treat a disease of this organ DERIVED · CC BY 4.0
Peripheral nervous system may treat a disease of this organ DERIVED · CC BY 4.0

4 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.